M John Chapman Selected Research

Cholesterol Esters (Cholesteryl Esters)

3/2012	Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy.
11/2010	Postprandial lipemia enhances the capacity of large HDL2 particles to mediate free cholesterol efflux via SR-BI and ABCG1 pathways in type IIB hyperlipidemia.
3/2008	Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity.
11/2006	Alterations in lipoprotein defense against oxidative stress in metabolic syndrome.
10/2004	Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity.
8/2003	Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
10/2002	Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state.
8/2002	Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
3/2002	LDL particle subclasses in hypercholesterolemia. Molecular determinants of reduced lipid hydroperoxide stability.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M John Chapman Research Topics

Disease

47	Atherosclerosis 01/2022 - 03/2002
41	Cardiovascular Diseases (Cardiovascular Disease) 12/2021 - 11/2003
31	Dyslipidemias (Dyslipidemia) 01/2022 - 02/2002
23	Atherosclerotic Plaque (Atheroma) 01/2020 - 01/2003
21	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 11/2003
21	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 10/2002
21	Inflammation (Inflammations) 01/2022 - 10/2002
15	Myocardial Infarction 01/2022 - 04/2002
12	Coronary Disease (Coronary Heart Disease) 12/2021 - 01/2003
12	Type 2 Diabetes Mellitus (MODY) 01/2020 - 08/2004
10	Insulin Resistance 01/2022 - 10/2004
10	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2020 - 04/2006
9	Hypercholesterolemia 10/2019 - 02/2002
9	Hyperlipidemias (Hyperlipidemia) 03/2012 - 08/2002
8	Hypertriglyceridemia 01/2022 - 02/2008
8	Obesity 01/2020 - 03/2008
5	Stroke (Strokes) 01/2021 - 09/2011
5	Acute Coronary Syndrome 01/2020 - 10/2002
5	Vascular Diseases (Vascular Disease) 05/2018 - 08/2002
5	Cholesteryl Ester Transfer Protein Deficiency 09/2017 - 02/2003
4	Ischemic Stroke 12/2021 - 01/2007
4	Pancreatitis 10/2020 - 08/2014
4	Unstable Angina 01/2020 - 01/2007
4	Hypertension (High Blood Pressure) 10/2014 - 03/2008
3	Aortic Valve Stenosis (Aortic Stenosis) 12/2021 - 10/2020
3	Homozygous Familial Hypercholesterolemia 10/2018 - 08/2014
3	Muscular Diseases (Myopathy) 05/2015 - 12/2005
3	Xanthomatosis (Xanthoma) 09/2014 - 12/2013
3	Rupture 01/2007 - 01/2003
2	Arteritis 01/2022 - 07/2007
2	Prediabetic State (Prediabetes) 01/2018 - 12/2015
2	Diabetes Mellitus 01/2018 - 06/2014
2	Disease Progression 06/2013 - 06/2011
2	Thrombosis (Thrombus) 04/2012 - 01/2007
2	Metabolic Diseases (Metabolic Disease) 01/2010 - 03/2006
2	Abdominal Obesity 03/2008 - 10/2004
2	Hepatocellular Carcinoma (Hepatoma) 08/2003 - 08/2002

Drug/Important Bio-Agent (IBA)

43	LipidsIBA 01/2022 - 03/2002
39	CholesterolIBA 12/2021 - 08/2002
39	oxidized low density lipoproteinIBA 01/2021 - 02/2002
37	HDL CholesterolIBA 01/2020 - 04/2002
35	Lipoproteins (Lipoprotein)IBA 01/2022 - 02/2002
34	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 08/2002
33	LDL CholesterolIBA 01/2021 - 02/2002
32	Triglycerides (Triacylglycerol)IBA 01/2022 - 08/2002
21	HDL LipoproteinsIBA 01/2022 - 08/2003
16	ApolipoproteinsIBA 01/2020 - 08/2003
16	Atorvastatin (Lipitor)FDA Link 10/2018 - 02/2002
15	LDL Lipoproteins (beta Lipoproteins)IBA 01/2020 - 10/2002
13	Apolipoprotein A-I (Apolipoprotein A1)IBA 05/2019 - 03/2006
12	Apolipoproteins B (ApoB)IBA 01/2020 - 08/2002
12	Rosuvastatin Calcium (Crestor)FDA Link 08/2017 - 01/2003
10	Cholesterol Ester Transfer ProteinsIBA 01/2018 - 10/2002
9	Cholesterol Esters (Cholesteryl Esters)IBA 03/2012 - 03/2002
8	C-Reactive ProteinIBA 05/2018 - 06/2006
7	Lipoprotein(a)IBA 12/2021 - 08/2012
7	Proteins (Proteins, Gene)FDA Link 05/2018 - 08/2003
6	Biomarkers (Surrogate Marker)IBA 01/2020 - 07/2005
6	Biological ProductsIBA 09/2015 - 10/2002
5	EnzymesIBA 01/2022 - 02/2002
5	Niacin (Nicotinic Acid)FDA LinkGeneric 05/2018 - 08/2004
5	Phospholipids (Phosphatides)FDA LinkGeneric 11/2016 - 12/2009
5	Phytosterols (Plant Sterols)IBA 05/2014 - 09/2007
5	Fibric Acids (Fibrates)IBA 09/2011 - 08/2003
4	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 10/2004
4	Proprotein Convertase 9IBA 01/2020 - 12/2016
4	LDL Receptors (LDL Receptor)IBA 01/2019 - 04/2006
4	Insulin (Novolin)FDA Link 05/2018 - 10/2004
4	Interleukin-6 (Interleukin 6)IBA 05/2018 - 09/2011
3	pitavastatin (itavastatin)FDA Link 01/2022 - 11/2011
3	omega-Chloroacetophenone (Mace)IBA 01/2020 - 11/2013
3	PCSK9 InhibitorsIBA 09/2019 - 12/2015
3	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 05/2018 - 03/2008
3	Serum Amyloid A Protein (Serum Amyloid A)IBA 09/2015 - 11/2006
3	Adenosine Triphosphate (ATP)IBA 03/2015 - 11/2011
3	CytokinesIBA 09/2014 - 04/2006
3	Apolipoproteins E (ApoE)IBA 04/2012 - 01/2006
3	Scavenger Receptors (Scavenger Receptor)IBA 10/2011 - 08/2003
2	eicosapentaenoic acid ethyl esterIBA 01/2022 - 01/2020
2	Apolipoprotein C-IIIIBA 05/2018 - 01/2016
2	ProteomeIBA 02/2016 - 09/2015
2	ATP-Binding Cassette Transporters (ABC Transporters)IBA 01/2016 - 10/2011
2	HDL3 LipoproteinsIBA 01/2016 - 08/2003
2	1-penicillamyl-Leu(2)- oxytocinIBA 08/2012 - 04/2012
2	PlasminogenIBA 04/2012 - 12/2010
2	Pharmaceutical PreparationsIBA 03/2012 - 08/2009
2	Pravastatin (Pravachol)FDA LinkGeneric 11/2011 - 01/2007
2	Simvastatin (Zocor)FDA LinkGeneric 11/2011 - 09/2011
2	Blood Glucose (Blood Sugar)IBA 06/2011 - 06/2006
2	Uric Acid (Urate)IBA 06/2011 - 06/2006
2	torcetrapibIBA 06/2008 - 01/2008
2	EmulsionsIBA 06/2004 - 02/2003
2	ChylomicronsIBA 06/2004 - 02/2003
2	Matrix Metalloproteinases (MMPs)IBA 02/2004 - 07/2003
2	VLDL LipoproteinsIBA 02/2003 - 10/2002
2	Dihydrotachysterol (AT 10)IBA 11/2002 - 08/2002

Therapy/Procedure

30	Therapeutics 01/2022 - 10/2002
6	Blood Component Removal (Apheresis) 10/2018 - 05/2010
5	Drug Therapy (Chemotherapy) 10/2018 - 03/2008
2	Secondary Prevention 01/2007 - 06/2004